GlassScriptPhysician profile
Cherian Sajan
NPI 1174764153
$12,833.35
in general payments reported to CMS, 2019-2025
52 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,841 · 2020: $1,359 · 2021: $3,415 · 2022: $1,662 · 2023: $1,342 · 2024: $2,199 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Travel and Lodging: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,748.20 |
| Travel and Lodging | $807.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $3,305.74 | 2019-2024 | Senza |
| Boston Scientific Corporation | $1,043.85 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Superion Indirect Decompression System |
| Curonix LLC | $1,000.18 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stimwave Technologies Incorporated | $750.89 | 2019-2022 | |
| Medtronic USA, INC. | $741.00 | 2019-2020 | |
| Nalu Medical, INC. | $665.16 | 2021-2025 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $650.49 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $640.21 | 2019-2025 | Ztlido |
| Ibsa Pharma INC. | $414.35 | 2020-2025 | Tirosint, Licart, Flector |
| Vertos Medical, INC. | $400.72 | 2020-2023 | Mild Device Kit |
| Abbott Laboratories | $352.13 | 2021-2025 | Proclaim, Eterna |
| Amgen INC. | $257.73 | 2019-2022 | |
| Medtronic, INC. | $257.69 | 2021-2023 | Kyphon Express II Kyphopak Tray |
| Globus Medical, INC. | $239.24 | 2025 | Senza, Vyrsa V1 |
| Grt US Holding, INC. | $230.70 | 2020-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherian Sajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.